Burning Rock Biotech (BNR) Accumulated Expenses (2019 - 2026)

Burning Rock Biotech's Accumulated Expenses history runs 8 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 4.07% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (up 4.07% YoY), while the FY2025 annual figure was $11.6 million, down 5.7% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $10.9 million, down from $11.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $24.4 million in Q4 2022, with the low at $10.5 million in Q2 2025.
• The 5-year median for Accumulated Expenses is $12.6 million (2024), against an average of $14.4 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses surged 77.94% in 2022, then slumped 44.98% in 2024.
• Burning Rock Biotech's Accumulated Expenses stood at $24.4 million in 2022, then sank by 40.37% to $14.6 million in 2023, then decreased by 14.51% to $12.5 million in 2024, then dropped by 8.5% to $11.4 million in 2025, then dropped by 4.15% to $10.9 million in 2026.
• Business Quant data shows BNR's Accumulated Expenses at $10.9 million in Q1 2026, $11.4 million in Q4 2025, and $10.8 million in Q3 2025.